Dm. Neville et al., INVIVO T-CELL ABLATION BY A HOLO-IMMUNOTOXIN DIRECTED AT HUMAN CD3, Proceedings of the National Academy of Sciences of the United Statesof America, 89(7), 1992, pp. 2585-2589
We have evaluated the in vivo efficacy of anti-CD3-CRM9, a holo-immuno
toxin constructed with a diphtheria toxin binding-site mutant. Eighty
percent of established human T-cell subcutaneous tumors in nude mice c
ompletely regressed following intraperitoneal injection of immunotoxin
at a dose set at half the minimum lethal dose assayed in toxin-sensit
ive animals. Similar regressions produced by a Cs-137 source required
a dose in excess of 500 cGy. The high degree of in vivo T-cell ablatio
n produced by this immunotoxin is apparently due to maintenance of the
toxin translocation function provided by CRM9 and a necessary intrace
llular routing function supplied by CD3. This immunotoxin may be usefu
l in treating conditions caused by pathologic oligoclonal T-cell expan
sion such as graft-versus-host disease, autoimmune diseases, and possi
bly AIDS.